市場調查報告書
商品編碼
1354295
乾眼症市場規模 - 按產品、疾病類型、分銷管道和預測,2023 - 2032 年Dry Eye Disease Market Size - By Product, By Disease Type, By Distribution Channel, & Forecast, 2023 - 2032 |
2023 年至 2032 年間,全球乾眼症市場複合年成長率將達到 7.4%。生活方式的改變、螢幕時間的增加和環境因素導致乾眼症盛行率上升。根據 NCBI 的數據,乾眼症 (DED) 是一種非常常見的眼部疾病,影響全世界大量人群,不同地理區域的盛行率從 5% 到 50% 不等。此外,全球老化人口數量不斷增加也支撐了市場。
乾眼症市場前景受益於持續的研究和開發努力,從而產生創新的治療方法和產品。此外,醫療保健專業人員和患者對 DED 的認知不斷提高,促進了早期診斷和治療,進一步刺激了市場成長。
整個乾眼症市場根據產品、疾病類型和地區進行分類。
2023 年至 2032 年,外用皮質類固醇細分市場的複合年成長率將達到 8.4%。這些藥物可有效緩解與 DED 相關的炎症,為患者提供急需的舒適感。隨著人們對 DED 及其治療方案認知的提高,加上人口老化的擴大,DED 市場對外用皮質類固醇的需求將持續上升。他們在控制乾眼症方面的作用有助於增加乾眼症市場的收入。
就疾病類型而言,從2023 年到2032 年,水液缺乏性乾眼症的複合年成長率將達到8%。這種乾眼症亞型是由於淚液產生減少而導致的,可能會導致嚴重不適。 ADDE 患者通常依靠專門的治療(例如人工淚液和處方藥)來有效控制病情。隨著 ADDE 認知和診斷的提高,DED 市場對標靶治療的需求持續成長。
2023 年至 2032 年,歐洲乾眼症市場複合年成長率將達到 7.2%。人口老化,加上螢幕時間增加和其他環境因素,將提高乾眼症的盛行率。根據歐盟統計局的數據,到 2022 年,超過五分之一(21.1%)的歐盟人口年齡在 65 歲及以上。此外,對醫療保健的日益關注以及 DED 治療和診斷的進步推動了市場擴張。隨著意識的增強,患者尋求有效的解決方案,從而增加了整個歐洲對 DED 相關產品和服務的需求。
Global Dry Eye Disease Market will witness 7.4% CAGR between 2023 and 2032. Changing lifestyles, increased screen time, and environmental factors contribute to a rising prevalence of DED. According to NCBI, dry eye disease (DED) is a highly common eye condition that impacts a substantial number of individuals worldwide, with its prevalence varying from 5% to 50% across different geographic regions. Additionally, a rising number of aging populations worldwide also supports the market.
The dry eye disease market outlook benefits from continuous research and development efforts, resulting in innovative treatments and products. Additionally, the growing awareness of DED among healthcare professionals and patients alike fosters early diagnosis and treatment, further stimulating market growth.
The overall Dry Eye Disease Market is classified based on product, disease type, and region.
The topical corticosteroids segment will witness an 8.4% CAGR from 2023 to 2032. These medications offer effective relief from inflammation associated with DED, providing much-needed comfort to patients. As awareness of DED and its management options increases, coupled with the expansion of aging populations, the demand for topical corticosteroids in the DED market will continue to rise. Their role in managing the condition contributes to the dry eye disease market revenue.
Regarding the disease type, the aqueous deficient dry eye syndrome segment will observe 8% CAGR from 2023 to 2032. This subtype of DED results from reduced tear production and can cause severe discomfort. Patients with ADDE often rely on specialized treatments, such as artificial tears and prescription medications, to manage their conditions effectively. As awareness and diagnosis of ADDE increase, the demand for targeted therapies within the DED market continues to grow.
Europe dry eye disease market will showcase 7.2% CAGR from 2023 to 2032. An aging population, in tandem with increased screen time and other environmental factors, elevates DED prevalence. According to Eurostat, in 2022, more than one-fifth (21.1 %) of the EU population was aged 65 and over. Furthermore, a growing focus on healthcare and advancements in DED treatments and diagnostics drive market expansion. As awareness grows, patients seek effective solutions, bolstering demand for DED-related products and services across Europe.